Targeted Oncology· @TargetedOnc · X·· 14 hours agoScore70
Body
A question about DeLLphi-305’s OS curves:
The experimental arm appears to decline steeply at later follow-up.
Is this simply a small numbers-at-risk effect, or could benefit wane over time?
I’d like to see late landmark survival, censoring and longer follow-up. #ESMO26
97 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com